A PR I L 1 8 - 2 0 , 2 0 1 9HILTON TOKYO BAY HOTELTOKYO, JAPAN

SUMMIT CHAIRS:Kensei Tobinai, MD, PhDVisiting ScientistNational Cancer Center HospitalTokyo, Japan

2nd Annual Global Summit on

MalignanciesHEMATOLOGIC

John Pagel, MD, PhDChief of Hematologic MalignanciesSwedish Cancer InstituteSeattle, Washington, USA

A PR I L 1 8 - 2 0 , 2 0 1 9HILTON TOKYO BAY HOTEL

TOKYO, JAPAN

2nd Annual Global Summit on

MalignanciesHEMATOLOGIC

James CS Chim, MD, PhDS H Ho Professorship in Hematology and OncologyUniversity of Hong KongHong Kong, China

Steve Coutré, MDProfessor of MedicineStanford University Medical CenterStanford, California, USA

Kiyoshi Eshima, MD, PhDFounder and PresidentDelta-fly PharmaTokushima, Japan

Hiroshi Handa, MD, PhDDirector, Department of HematologyGunma University Graduate School of MedicineMaebashi, Japan

Naoki Hosen, MD, PhDAssociate Professor, Department of Cancer Stem Cell BiologyOsaka University Graduate School of MedicineOsaka, Japan

Jiong HuDeputy Director, Department of HematologyRui Jin HospitalShanghai, China

Erlie Jiang, MD, PhDProfessorInstitute of Hematology & Blood Diseases HospitalTianjin, China

Yoshinobu Kanda, MD, PhDProfessor of MedicineJichi Medical UniversityShimotsuke, Japan

Seok Jin Kim, MDProfessor of Hematology and OncologySamsung Medical Center, Sungkyunkwan UniversitySeoul, South Korea

Won Seog Kim, MD, PhDProfessor of Hematology and OncologySamsung Medical Center, Sungkyunkwan UniversitySeoul, South Korea

Zhiming Li, MD, PhDProfessorSun Yat-sen University Cancer CenterGungzhou, China

Yosuke Minami, MD, PhDChief, Department of HematologyNational Cancer Center Hospital EastTokyo, Japan

Stephen Mulligan, MBBS, PhDAdjunct Professor, Senior Staff Specialist and HematologistUniversity of SydneySydney, Australia

Wataru Munakata, MD, PhDStaff PhysicianNational Cancer Center HospitalTokyo, Japan

Hirokazu Murakami, MDDepartment of Laboratory ScienceGunma University Graduate School of Health ScienceMaebashi, Japan

Michinori Ogura, MD, PhDDirector, Department of Hematology and OncologyKasugai Municipal HospitalAichi, Japan

Keiya Ozawa, MD, PhDProfessor of MedicineJichi Medical UniversityShimotsuke, Japan

John Pagel, MD, PhD CHAIRChief of Hematologic MalignanciesSwedish Cancer InstituteSeattle, Washington, USA

Nina Shah, MDAssociate ProfessorUniversity of California San FranciscoSan Francisco, California, USA

Kazuyuki Shimizu, MD, PhDAdvisor and Supervisor, Department of Hematology and OncologyHigashi Nagoya National HospitalNagoya, Japan

Kensei Tobinai, MD, PhD CHAIRVisiting ScientistNational Cancer Center HospitalTokyo, Japan

Noriko Usui, MD, PhDProfessorDepartment of Clinical Oncology and HematologyThe Jikei University Daisan HospitalTokyo, Japan

Jue WangTongji Hospital of Huazhong University of Science and TechnologyWuhan, China

Kazuhito Yamamoto, MD, PhDChief, Department of Hematology and Cell TherapyAichi Cancer CenterAichi, Japan

Xian Zhang, MDChief PhysicianLudaopei HospitalBeijing, China

FACULTY

MEETING OVERVIEW

Oncology Meeting Innovation’s (OMI’s) Global Summit on Hematologic Malignancies fosters discussion and debate on the evolution of treatment and features a focused approach towards individual patient populations through case-based discussions. New agents targeting BTK, PI3K delta, and BCL-2, as well as next-generation CD20 monoclonal antibodies, are changing the landscape and treatment paradigms for CLL. Similarly, recent data on drugs targeting CD38, SLAMF7, and HDAC, as well as novel approaches to proteasome inhibition, are advancing the continuum of treatment within multiple myeloma. Furthemore, advances in the understanding of the molecular biology and microenvironment have led to new approaches to treating lymphonma. Compelling data on the effects of novel strategies, such as CAR-T therapy, checkpoint inhibition, and next-generation antibody therapy, have led to an explosion of new information and agents in development for patients with hematologic malignancies. In response to these changes, the summit assembles translational researchers, clinical researchers, and key community oncologists to address the challenges of this rapidly evolving area of oncology.

A PR I L 1 8 - 2 0 , 2 0 1 9HILTON TOKYO BAY HOTEL

TOKYO, JAPAN

2nd Annual Global Summit on

MalignanciesHEMATOLOGIC

Thursday, April 18, 20195:00 PM Welcome and Introductions

SETTING THE STAGE5:15 PM The Development on Novel BTK Inhibitors5:30 PM What is new is FL in 2019?5:45 PM Advances in Salvage Therapy in DLBCL

in 20196:00 PM Uncovering New Targets for the

Treatment of Multiple Myeloma6:15 PM Advances in the Treatment of Hodgkins

Disease6:30 PM Future of FLT3 Treatment in AML6:45 PM DISCUSSION7:45 PM ADJOURN TO RECEPTION

Friday, April 19, 20197:00 AM BREAKFAST

T-CELL LYMPHOMAS8:00 AM Phase II Study of Gemcitabine, Peg-

asparaginase, Dexamethasone and Methotrexate for Newly Diagnosed Extranodal Natural Killer/T-cell Lymphoma, Nasal Type

8:15 AM Targeting Therapy of T-cell Lymphoma: Recent Progress

8:30 AM How do we Improve Therapeutic Efficacy for PTCLs?

8:45 AM DISCUSSION9:30 AM BREAK

CHRONIC LYMPHOCYTIC LEUKEMIA9:45 AM The Role of Single-agent Ibrutinib in CLL

in 2019 and Future Combinations10:00 AM Resistance Mechanisms in CLL in Novel

Rx Era10:15 AM Emerging Data on PI3K Resistance in

CLL 10:30 AM DISCUSSION

MRD IN HEMATOLOGIC MALIGNANCIES11:15 AM What is the Role of MRD in CLL11:25 AM What is the Best Method for MRD in

Myeloma11:35 AM How Low do you go with MRD in AML11:45 AM DISCUSSION

12:15 PM LUNCH

INDOLENT LYMPHOMAS1:15 PM Integrating BTK and Other New Targets in

MCL1:30 PM Recent Progress in Treatment of Newly

Diagnosed Advanced FL1:45 PM Improving Survival afer

Chemoimmunotherapy with BCL2 Inhibitors

2:00 PM Role of PD-1 and PD-L1 Therapy in Hodgkin’s Lymphoma

2:15 PM DISCUSSION

A PR I L 1 8 - 2 0 , 2 0 1 9HILTON TOKYO BAY HOTEL

TOKYO, JAPAN

2nd Annual Global Summit on

MalignanciesHEMATOLOGIC

Friday, April 19, 2019 (cont.)DLBCL

3:15 PM Trials to Improve R-CHOP in DLBCL3:30 PM CAR-T Therapy for DLBCL3:45 PM DLBCL Classifications in 20194:00 PM DISCUSSION4:45 PM BREAK

MULTIPLE MYELOMA5:00 PM Role of Daratumumab in Frontline

Multiple Myeloma5:15 PM Global Genomics in Multiple Myeloma5:30 PM Non-coding RNA in Multiple Myeloma5:45 PM Clinical Responses and Pharmacokinetics

of Fully Human BCMA Targeting CAR-T Cell Therapy in R/R MM

6:00 PM Evolution of M-protein measurement6:15 PM New Targets for Myeloma Therapy6:30 PM What’s Next for CAR-T in Multiple

Myeloma?6:45 PM DISCUSSION

DEBATING CAR-T TECHNOLOGY7:30 PM Finding a Role for Current CAR-T

Technology7:40 PM Necessity of Optimizing CAR-T

Technology7:50 PM PANEL DISCUSSION8:30 PM ADJOURN TO POSTER RECEPTION

Saturday, April 20, 20197:00 AM BREAKFAST

ACUTE LEUKEMIAS

8:00 AM New Approaches to Allogenic SCT for MDS and MPN

8:15 AM Advances in Allogenic SCT fro R/R AML8:30 AM Efficacy and Safety of CD19 CAR-T Cell

Therapy for B-cell ALL in a Large Cohort Including Patients with Extramedullary Disease (EMD), High Leukemia Burden, BCR-ABL (+) Mutation, TP53 Mutation, and Post-Transplant Relapse

8:45 AM BREAK9:00 AM Next-generation FLT3 Inhibitors in AML9:15 AM Precision Medicine in AML9:30 AM Is the Age of 7+3 Coming to an End?9:45 AM DISCUSSION

EMERGING AGENT SHOWCASE11:00 AM Module Technology for Hematological

Cancer11:15 AM Emerging Agent 211:30 AM Emerging Agent 311:45 AM Emerging Agent 412:00 PM DISCUSSION12:30 PM ADJOURN